TGFB1 and chronic kidney disease: As many factors associated with the CASP are known to induce fibrosis in the kidney (e.g., TGFβ, interleukin (IL)-1, and interleukin (IL)-6), targeting upstream of these inflammatory signalling intermediates might prove an effective alternative strategy for CKD treatment.